A California appellate court's decision on generic drug liability -- which the state Supreme Court declined to review last week -- upended 14 years of precedent, according to an article in Inside Counsel magazine.
The article, published before the Supreme Court's decision was made public, makes several interesting points about Conte v. Wyeth.
First, some background: The plaintiff in the case sued Wyeth for her injuries even though she took a generic version of a drug that Wyeth pioneered but didn't sell to her. The appeals court's decision is at odds with traditional tort liability, which holds that fundamentally manufacturers are responsible for their own products but not responsible for the products made by competitors.
From Inside Counsel:
- The appeals court decision departs from more than a decade of case law in other jurisdictions. The court, however, wrote that it was rooted in "common sense and California common law."
- Given the nature of the pharmaceutical market, in which it's not uncommon for generics to have 80% or 90% of the market share over time, such a specter could surely dampen pioneer companies' willingness to innovate, Mark Haddad, a partner in Sidley Austin and chair of the firm's appellate practice group, told the magazine.
- The case could have broad implications outside the pharmaceutical arena. "If there's a sufficient similarity between whatever product the consumer ultimately uses and whatever product the entity in question is making a statement about, the court could say it's foreseeable that statements about Product X could impact on the consumer's decision to buy or use Product Y," Haddad said.